Does perioperative chemotherapy improve survival in upper tract urothelial carcinoma? A population based analysis

Hanan Goldberg, Zachary W A Klaassen, Thenappan Chandrasekar, Rashid Sayyid, Girish S. Kulkarni, Robert J. Hamilton, Neil E. Fleshner

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objectives: To evaluate the utilization and outcomes of perioperative chemotherapy in non-metastatic UTUC patients over the past decade using a large national database. Methods: All patients aged 18 and older diagnosed with non-metastatic UTUC between 2004 and 2013 were identified within the Surveillance, Epidemiology and End Results (SEER) database. Relevant clinical data was collected and predictors of cancer specific mortality (CSM) and other cause mortality (OCM) were analyzed. Results: The total cohort included 8,762 patients. Of these, 1,402 (16%) patients received chemotherapy, including only 35% of high-risk patients ( > pT2 or N1). Treated patients had higher CSM (21.3% vs. 13.1%, p < 0.001). Predictors of chemotherapy utilization included residence in Midwest states, tumor located in the ureter, higher stage and grade. Predictors of CSM included older age, residence in southern states, receipt of chemotherapy (HR = 1.151, 95% CI: 1.003-1.32, p=0.044), higher stage and grade. OCM was predicted by male gender, older age, ureteral tumor, and higher stage. A subset analysis of patients younger than 65 showed similar predictors, while an analysis of high risk patients demonstrated that chemotherapy receipt did not predict CSM or OCM. Conclusions: In this large contemporary non-metastatic UTUC cohort, chemotherapy utilization was found to be quite infrequent, but increasing steadily. Perioperative chemotherapy had no effect on CSM in high-risk patients, while correlated to higher CSM in the younger patients.

Original languageEnglish (US)
Pages (from-to)18797-18810
Number of pages14
JournalOncotarget
Volume9
Issue number27
DOIs
StatePublished - Apr 10 2018
Externally publishedYes

Fingerprint

Carcinoma
Drug Therapy
Survival
Mortality
Population
Neoplasms
Databases
Ureter
Epidemiology

Keywords

  • Cancer specific mortality
  • Chemotherapy
  • Other cause mortality
  • Upper tract urothelial carcinoma

ASJC Scopus subject areas

  • Oncology

Cite this

Goldberg, H., Klaassen, Z. W. A., Chandrasekar, T., Sayyid, R., Kulkarni, G. S., Hamilton, R. J., & Fleshner, N. E. (2018). Does perioperative chemotherapy improve survival in upper tract urothelial carcinoma? A population based analysis. Oncotarget, 9(27), 18797-18810. https://doi.org/10.18632/oncotarget.24694

Does perioperative chemotherapy improve survival in upper tract urothelial carcinoma? A population based analysis. / Goldberg, Hanan; Klaassen, Zachary W A; Chandrasekar, Thenappan; Sayyid, Rashid; Kulkarni, Girish S.; Hamilton, Robert J.; Fleshner, Neil E.

In: Oncotarget, Vol. 9, No. 27, 10.04.2018, p. 18797-18810.

Research output: Contribution to journalArticle

Goldberg, H, Klaassen, ZWA, Chandrasekar, T, Sayyid, R, Kulkarni, GS, Hamilton, RJ & Fleshner, NE 2018, 'Does perioperative chemotherapy improve survival in upper tract urothelial carcinoma? A population based analysis', Oncotarget, vol. 9, no. 27, pp. 18797-18810. https://doi.org/10.18632/oncotarget.24694
Goldberg, Hanan ; Klaassen, Zachary W A ; Chandrasekar, Thenappan ; Sayyid, Rashid ; Kulkarni, Girish S. ; Hamilton, Robert J. ; Fleshner, Neil E. / Does perioperative chemotherapy improve survival in upper tract urothelial carcinoma? A population based analysis. In: Oncotarget. 2018 ; Vol. 9, No. 27. pp. 18797-18810.
@article{65807a39e3b044f1887787f90382a36b,
title = "Does perioperative chemotherapy improve survival in upper tract urothelial carcinoma? A population based analysis",
abstract = "Objectives: To evaluate the utilization and outcomes of perioperative chemotherapy in non-metastatic UTUC patients over the past decade using a large national database. Methods: All patients aged 18 and older diagnosed with non-metastatic UTUC between 2004 and 2013 were identified within the Surveillance, Epidemiology and End Results (SEER) database. Relevant clinical data was collected and predictors of cancer specific mortality (CSM) and other cause mortality (OCM) were analyzed. Results: The total cohort included 8,762 patients. Of these, 1,402 (16{\%}) patients received chemotherapy, including only 35{\%} of high-risk patients ( > pT2 or N1). Treated patients had higher CSM (21.3{\%} vs. 13.1{\%}, p < 0.001). Predictors of chemotherapy utilization included residence in Midwest states, tumor located in the ureter, higher stage and grade. Predictors of CSM included older age, residence in southern states, receipt of chemotherapy (HR = 1.151, 95{\%} CI: 1.003-1.32, p=0.044), higher stage and grade. OCM was predicted by male gender, older age, ureteral tumor, and higher stage. A subset analysis of patients younger than 65 showed similar predictors, while an analysis of high risk patients demonstrated that chemotherapy receipt did not predict CSM or OCM. Conclusions: In this large contemporary non-metastatic UTUC cohort, chemotherapy utilization was found to be quite infrequent, but increasing steadily. Perioperative chemotherapy had no effect on CSM in high-risk patients, while correlated to higher CSM in the younger patients.",
keywords = "Cancer specific mortality, Chemotherapy, Other cause mortality, Upper tract urothelial carcinoma",
author = "Hanan Goldberg and Klaassen, {Zachary W A} and Thenappan Chandrasekar and Rashid Sayyid and Kulkarni, {Girish S.} and Hamilton, {Robert J.} and Fleshner, {Neil E.}",
year = "2018",
month = "4",
day = "10",
doi = "10.18632/oncotarget.24694",
language = "English (US)",
volume = "9",
pages = "18797--18810",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "27",

}

TY - JOUR

T1 - Does perioperative chemotherapy improve survival in upper tract urothelial carcinoma? A population based analysis

AU - Goldberg, Hanan

AU - Klaassen, Zachary W A

AU - Chandrasekar, Thenappan

AU - Sayyid, Rashid

AU - Kulkarni, Girish S.

AU - Hamilton, Robert J.

AU - Fleshner, Neil E.

PY - 2018/4/10

Y1 - 2018/4/10

N2 - Objectives: To evaluate the utilization and outcomes of perioperative chemotherapy in non-metastatic UTUC patients over the past decade using a large national database. Methods: All patients aged 18 and older diagnosed with non-metastatic UTUC between 2004 and 2013 were identified within the Surveillance, Epidemiology and End Results (SEER) database. Relevant clinical data was collected and predictors of cancer specific mortality (CSM) and other cause mortality (OCM) were analyzed. Results: The total cohort included 8,762 patients. Of these, 1,402 (16%) patients received chemotherapy, including only 35% of high-risk patients ( > pT2 or N1). Treated patients had higher CSM (21.3% vs. 13.1%, p < 0.001). Predictors of chemotherapy utilization included residence in Midwest states, tumor located in the ureter, higher stage and grade. Predictors of CSM included older age, residence in southern states, receipt of chemotherapy (HR = 1.151, 95% CI: 1.003-1.32, p=0.044), higher stage and grade. OCM was predicted by male gender, older age, ureteral tumor, and higher stage. A subset analysis of patients younger than 65 showed similar predictors, while an analysis of high risk patients demonstrated that chemotherapy receipt did not predict CSM or OCM. Conclusions: In this large contemporary non-metastatic UTUC cohort, chemotherapy utilization was found to be quite infrequent, but increasing steadily. Perioperative chemotherapy had no effect on CSM in high-risk patients, while correlated to higher CSM in the younger patients.

AB - Objectives: To evaluate the utilization and outcomes of perioperative chemotherapy in non-metastatic UTUC patients over the past decade using a large national database. Methods: All patients aged 18 and older diagnosed with non-metastatic UTUC between 2004 and 2013 were identified within the Surveillance, Epidemiology and End Results (SEER) database. Relevant clinical data was collected and predictors of cancer specific mortality (CSM) and other cause mortality (OCM) were analyzed. Results: The total cohort included 8,762 patients. Of these, 1,402 (16%) patients received chemotherapy, including only 35% of high-risk patients ( > pT2 or N1). Treated patients had higher CSM (21.3% vs. 13.1%, p < 0.001). Predictors of chemotherapy utilization included residence in Midwest states, tumor located in the ureter, higher stage and grade. Predictors of CSM included older age, residence in southern states, receipt of chemotherapy (HR = 1.151, 95% CI: 1.003-1.32, p=0.044), higher stage and grade. OCM was predicted by male gender, older age, ureteral tumor, and higher stage. A subset analysis of patients younger than 65 showed similar predictors, while an analysis of high risk patients demonstrated that chemotherapy receipt did not predict CSM or OCM. Conclusions: In this large contemporary non-metastatic UTUC cohort, chemotherapy utilization was found to be quite infrequent, but increasing steadily. Perioperative chemotherapy had no effect on CSM in high-risk patients, while correlated to higher CSM in the younger patients.

KW - Cancer specific mortality

KW - Chemotherapy

KW - Other cause mortality

KW - Upper tract urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85045221298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045221298&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.24694

DO - 10.18632/oncotarget.24694

M3 - Article

AN - SCOPUS:85045221298

VL - 9

SP - 18797

EP - 18810

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 27

ER -